AstraZeneca to Evaluate Compendia's Oncomine Software

Dec 04, 2007

NEW YORK (GenomeWeb News) - AstraZeneca has licensed Compendia Bioscience’s data mining and visualization software, Compendia said today.

AstraZeneca will use the company’s Oncomine Concepts Edition software in a year-long pilot program in order to evaluate how it can be used in its cancer research programs.

Oncomine combines almost 7,000 proprietary cancer gene signatures with 11,000 gene, drug, and pathway signatures taken from the literature and other public sources, Compendia said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

No More

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

Dunno What Those Do

New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.

HeLa Variety

The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.

This Week in Nature

In Nature this week: protein-coding variants associated with body-fat distribution, and more.

Main menu